Lantheus Medical Imaging parent company Lantheus Holdings reported a 121.4% increase in revenue in its 2022 second quarter, as well as net income compared to a net loss in 2021.
For the period (end-June 30), Lantheus posted worldwide revenue of $223.7 million, up from $101.1 million in the second quarter of 2021. In quarterly highlights, sales of its Definity echocardiography contrast agent exceeded pre-COVID-19 levels, according to the company.
The company reported net income of $43.1 million for the quarter, compared to a net loss of $26.7 million in the same period a year ago.
For the six months ended June 30, the company reported revenues of $432.6 million compared to $193.6 million during the same period last year, and net income of $86 million compared to a net loss of $17.6 million in 2021.
Looking ahead, Lantheus has increased its full-year revenue and earnings estimates. The vendor now expects 2022 revenue will range between $885 million and $905 million, compared with the previous estimated range of $800 million to $835 million, it said.
